Immunicum Shares Rise on Cancer Vaccine Progress
Shares in Immunicum AB surged more than 40 percent Monday on promising signals from a Phase I/II trial of its kidney cancer vaccine, Intuvax. The optimism is based on preliminary data from a very small-scale study. The open-label trial recruited just 12 patients with metastatic renal cancer.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter